“We view OPT’s shares as significantly undervalued given the potential of sozinibercept in wet AMD, which has been demonstrated in multiple clinical trials. With the completion of enrollment in the COAST trial and data expected in 2H25, we believe OPT is poised for a re-rating as investors gain confidence in the clinical program… We see a favorable risk/reward at current levels and view OPT as a top pick among our small cap ophthalmology names,” Singh noted.
Singh rates OPT an Outperform (i.e., Buy) along with a $30 price target, implying an upside potential of 650% over the next year. (To watch Singh’s track record, click here)
Wall Street is bullish on this penny stock as well. With 3 Buy ratings vs no Holds or Sells, OPT stock has a Strong Buy consensus rating. The average price target stands at $29.33, suggesting a one-year upside of 640%. (See OPT stock analysis on TipRanks)
Both TARA and OPT have a strong backing on Wall Street, with analysts predicting significant upside potential for both penny stocks. While the risks are high, the potential rewards are even higher, making these stocks intriguing plays for investors looking for substantial gains.
He highlights the early achievements in safety profiling and praises the company and its drug candidate, stating, “We believe that OPT possesses key qualities we look for in a small-cap biotech company: a management team focused on execution, validated science and technology, and promising early/mid-stage clinical data. Sozinibercept shows potential to improve vision in addition to existing anti-VEGFA treatments, with a well-tolerated safety profile based on strong Phase 2B results. Unlike other emerging approaches in wAMD that prioritize durability, sozinibercept is unique in aiming to enhance vision.”
In line with his positive outlook, Singh rates OPT shares as Outperform (Buy) with a target price of $18, indicating a substantial 447% potential upside in one year.
Overall, Opthea has received 3 favorable analyst reviews, resulting in a Strong Buy consensus rating for its shares. Currently trading at $3.30, the stock has an average price target of $16, suggesting a potential gain of around 385% in the coming year.
For investors seeking penny stocks with attractive valuations, TipRanks’ Best Stocks to Buy tool offers valuable insights and recommendations.
Please note that the opinions expressed in this article are those of the featured analysts and should be used for informational purposes only. It is essential to conduct your own research before making any investment decisions.